Caris Life Sciences Human Leukocyte Antigen Genotype Reporting
Caris Life Sciences has launched Human Leukocyte Antigen (HLA) Genotype reporting. The product strengthens physicians' ability to provide more individualized treatment decisions for their patients, and the results may also provide additional insight for patient enrollment into clinical trials and patients' response to immunotherapy, the company said.
Effective immediately, HLA Genotype results will be reported as a genomic signature, along with tumor mutational burden, microsatellite instability, and loss of heterozygosity as standard reporting elements for patients profiled by Caris.
Qlucore Omics Explorer Version 3.7
Qlucore has introduced version 3.7 of its Qlucore Omics Explorer, which the company dubbed an "extensive upgrade" to its flagship bioinformatics product. The new release adds support for ChIP-seq and ATAC-seq analysis. It also features new visualizaton functions and a redesigned statistical framework for the built-in genome browser, plus a redesigned biomarker workbench that has been optimized for biomarker discovery and drug development.
Biocartis Idylla GeneFusion Assay
Biocartis has launched its Idylla GeneFusion Assay. The firm said the research-use-only test analyzes a wide range of biomarkers covering all gene fusions considered to be relevant in cancer research, including ALK, ROS1, RET, NTRK1/2/3 fusions, and MET exon 14 skipping mutations. Biocartis' test, which produces results within three hours, is the first formalin-fixed, paraffin-embedded RNA-based assay on Biocartis' Idylla platform.
For more new products and services, please visit the New Products page on our website.